The procurement cycle for a preclinical immuno-oncology asset runs in years, not quarters, and the budget owner is eventually a pharma BD team that wants to see clean translational data before it writes a term sheet. That is the buyer Ventuno Biotech is quietly building toward, and the €3M seed it closed in November is the working capital meant to get it to the conversation [European Biotechnology, Nov 2025].
The Lyon-headquartered company, founded in February 2025, is not chasing a platform story or a software-style growth chart. It is a translational research bet, hosted inside one of France's better-known cancer research centers, with a corporate investor as both co-founder and president [Ventuno Biotech, Feb 2025].
The bet on resistant tumors
Ventuno's stated focus is cancer immunotherapies aimed at difficult-to-treat tumors and cancers resistant to current treatments [Ventuno Biotech, retrieved 2025]. The company describes the work as developing first-in-class immuno-oncology assets and novel therapeutic antibodies, with the near-term goal of moving its preclinical pipeline toward later-stage development [European Biotechnology, Nov 2025] [Biotech Finances, retrieved 2026].
That framing matters because it tells you what kind of buyer Ventuno is eventually selling to. First-in-class assets are licensed, partnered, or acquired. They are not sold into a procurement portal. The seed round is, in plain terms, runway to generate the preclinical package that gives a future partner a reason to engage.
How the round is built
The €3M is not all equity. It is structured as €2M in equity, led by Octalfa with participation from Relyens Innovation Santé and others, plus €1M in loans [European Biotechnology, Nov 2025]. For a preclinical biotech in 2025, that mix is a pragmatic answer to a tight European biotech financing market: dilute less now, layer in non-dilutive debt, and push the next valuation event further out.
Equity | 2 | M EUR
Loans | 1 | M EUR
The equity syndicate is local and strategic rather than tier-one venture. Octalfa is both lead investor and a founding entity; Relyens Innovation Santé brings a healthcare-mutual lens; Caisse d'Epargne Rhône Alpes and BNP Paribas Innovation round out the regional banking exposure, with Gilles Alberici and Armand Bensussan named as individual backers [European Biotechnology, Nov 2025].
The IRCM connection
The single most important asset on the cap table is not on the cap table. Ventuno's research laboratories sit inside the Montpellier Cancer Research Institute, IRCM, and animal experimentation runs at Sanofi Biopark in Montpellier [Eurobiomed, retrieved 2026]. Co-founder Nathalie Bonnefoy is Director of the IRCM Research Center, which collapses the usual academic-to-startup tech transfer distance to roughly zero [Ventuno Biotech, retrieved 2025].
This is a meaningful structural advantage at seed stage. Preclinical biotechs spend real money standing up wet-lab capacity. Ventuno gets to deploy capital into experiments rather than into facilities, and its scientific co-founder is the person who runs the institute hosting the work.
The team and the corporate parent
The founding structure is unusual enough to spell out plainly. Octalfa, an investment company, is listed as a co-founder and serves as President of Ventuno [Ventuno Biotech, Feb 2025]. Julien Alberici, Octalfa's General Manager, represents the firm in the founding team [Turenne Groupe, retrieved 2026] [LinkedIn, retrieved 2026].
| Name | Role at Ventuno | Affiliation |
|---|---|---|
| Jeremy Bastid | Co-founder & CEO | Director of R&D, Octalfa [Bloomberg, retrieved 2026] |
| Nathalie Bonnefoy | Co-founder | Director, IRCM Research Center [Ventuno Biotech, 2025] |
| Julien Alberici | Co-founder (rep. Octalfa) | General Manager, Octalfa [Turenne Groupe, 2026] |
| Octalfa | Co-founder & President | Investment company, lead seed investor [Ventuno Biotech, 2025] |
This is effectively an Octalfa-incubated company with an embedded academic principal investigator. Biotech Finances describes Octalfa as a founding member and incubator of Ventuno, which is consistent with the structure on display [Biotech Finances, retrieved 2026].
What could go wrong
A pragmatic read has to weigh the obvious risks against the obvious assets. The company is real, the science host is real, and the funding is closed. The path from here is the hard part.
- Single-asset exposure at seed. A €3M seed in preclinical immuno-oncology is enough to advance a lead program but not enough to build a hedged pipeline. The next financing event will likely need to clear a higher bar than a typical software Series A, because the data package is the product.
- Concentrated governance. Octalfa is co-founder, president, and lead investor. That alignment is useful for speed and unusual for independence; a later institutional lead may want to renegotiate the structure.
- No disclosed clinical timeline. Public materials describe an intent to accelerate the preclinical pipeline toward later-stage development, but no IND-enabling date or candidate nomination has been disclosed [European Biotechnology, Nov 2025]. The renewal motion here, to borrow a term that does not quite belong, is a future partnership conversation that requires data Ventuno does not yet have in public.
- Regional syndicate. The current backers are credible in France, but a Series A in immuno-oncology typically requires a specialist transatlantic biotech investor at the table. That syndicate is still to be built.
The next twelve months
The milestones to watch are concrete. A named lead candidate. A preclinical proof-of-concept readout. A first scientific publication from the IRCM-hosted work. Any hint of an early discovery-stage collaboration with a larger pharma. Each of those would reset the valuation conversation before the next round.
The ideal customer profile for Ventuno's eventual output is unambiguous: oncology business development teams at mid-cap and large-cap pharma looking for differentiated, mechanism-novel immuno-oncology assets they did not have to discover in-house. That is a small, identifiable list of buyers, which is both the comfort and the constraint of this kind of company.
The realistic competitive set is not other Lyon seed-stage biotechs. It is the global cohort of preclinical immuno-oncology startups competing for the same partnership slots: French peers spun out of Institut Curie and Gustave Roussy, European antibody discovery shops with their own IRCM-equivalent hosts, and US specialists working the resistant-tumor angle with deeper Series A syndicates already in place. Ventuno's case for that audience will rest on the specificity of its assets and the credibility of the IRCM-anchored translational data, not on the size of this seed.
Sources
- [European Biotechnology, November 2025] Ventuno Biotech Secures €3m to Power Next-Gen Cancer Immunotherapies | https://european-biotechnology.com/latest-news/ventuno-biotech-secures-euro-3m/
- [Ventuno Biotech, February 2025] Launch of Ventuno Biotech | https://ventuno-biotech.com/news/launch-of-ventuno-biotech/
- [Ventuno Biotech, retrieved 2025] About us | https://ventuno-biotech.com/about-us/
- [Biotech Finances, retrieved 2026] Outils d'intéressement des start-ups, Ventuno biotech, Octalfa | https://biotech-finances.com/outils-dinteressement-des-start-ups-ventuno-biotech-octalfa-jean-laurent-casanova-novo-nordisk/
- [Eurobiomed, retrieved 2026] Quand les biotechs montpelliéraines innovent pour les soins de demain | https://www.eurobiomed.org/en/actualites/quand-les-biotechs-montpellieraines-innovent-pour-les-soins-de-demain/
- [Bloomberg Markets, retrieved 2026] Jeremy Bastid, Octalfa: Profile and Biography | https://www.bloomberg.com/profile/person/17184471
- [Turenne Groupe, retrieved 2026] Ventuno Biotech sécurise 3 M€ en amorçage | https://www.turennecapital.com/ventuno-biotech-securise-3-me-en-amorcage-pour-accelerer-le-developpement-de-nouvelles-immunotherapies-contre-le-cancer/
- [LinkedIn, retrieved 2026] Julien Alberici, Octalfa | https://www.linkedin.com/in/julien-alberici-9baa9267/